Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Despite the 280 percent year-to-date gains in Puma Biotechnology Inc (NASDAQ:PBYI) shares, Citigroup is projecting shares could go higher.
Citi maintained its Buy on Puma Biotechnology and raised its price target from $114 to $156.
At the time of writing, shares of Puma Biotechnology were up 0.41 percent at $123.50.
Shares Up 102% Since FDA Approval
The NALA study is a clinical trial for testing Puma's investigational drug neratinib, known as Nerlynx, when given as a combo treatment with the approved breast cancer drug capecitabine. The patient population consists of adults who have received at least two previous HER2-directed treatments for metastatic breast cancer.
Puma Biotechnology's shares have been up 102 percent since late May, when an FDA panel voted 12 to 4 in favor of approving neratinib, said Citi analyst Yigal Nochomovitz. The shares have ran up about 40 percent since the FDA approved Nerlynx for the extended adjuvant treatment of early-stage HER2-positive breast cancer on July 17. An extended adjuvant therapy is one which is taken after an initial treatment to further lower the risk of relapse. (See Nochomovitz' track record here.)
An Acquisition Target?
Puma shares have eclipsed Citi's previous $114 price target, Nochomovitz said, adding that Citi identified the company as an acquisition target as early as the first quarter of 2016.
Citi is ready to "fully flex" its acquisition thesis, which took its price target to $156, the analyst said. This, according to the firm, would make Puma Biotechnology a $6 billion company. Citi's projected peak adjuvant revenues for Nerlynx of about $1.4 billion implies only a 4x multiple.
"If Puma raises debt, that is fine," Nochomovitz said. Five out of the eight acquired firms highlighted by Citi have had an appreciable debt-to-cash ratio, the analyst said.
Related Links:
Attention Biotech Investors, Here's Your PDUFA Primer For October
The Current State Of The Breast Cancer Treatment Space
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!